loading...| Preferred Name |
ceritinib |
|
| Synonyms |
LDK378 |
|
| Definitions |
An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C115112" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C115112" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000694589 |
|
| altLabel |
LDK378 LDK 378 2,4-pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)- Zykadia |
|
| CAS Registry |
1032900-25-6 |
|
| cui |
C3819074 C3818721 C3852624 |
|
| DATE FIRST PUBLISHED |
2011-01-28 |
|
| Date last modified |
2016-05-09 |
|
| definition |
An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C115112" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C115112" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C115112 |
|
| notation |
CDR0000694589 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
ceritinib |
|
| tui |
T109 T121 |